PharmaTher's Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)

Stock Information for Pharmadrug Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pharmadrug Inc.

PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
PharmaDrug Announces Issuance of Debenture Units
PharmaDrug Announces Proposed Issuance of Debenture Units
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaTher's Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.